Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod at ECCO 2026 Alongside IBD Clinical Data

on

Abivax announced 22 abstracts on obefazimod for IBD at ECCO 2026 Congress (Feb 18-21, Stockholm), including an oral presentation on first preclinical evidence of anti-fibrotic activity.12

Oral presentation by Prof. Silvio Danese on Feb 21:
Obefazimod showed ~50% reduction in fibrosis biomarker Pro-C3 (p<0.0001) and ~30% in activation marker αSMA (p<0.0001) in human fibroblast model, plus effects in TNBS-colitis mouse model.12

Subgroup analyses from Phase 3 ABTECT induction trials show obefazimod's efficacy across UC patient subpopulations, early symptomatic improvements from week 1, downregulation of IL-17A and IL-6, and favorable safety profile comparable to placebo in 1,272 patients.124

Anti-fibrotic data addresses unmet need in Crohn's disease fibrosis, potentially reducing strictures and surgery needs.13

CEO Marc de Garidel highlighted the robust data depth from ABTECT trials and obefazimod's potential beyond inflammation.15

Sources:

1. https://www.globenewswire.com/news-release/2025/12/17/3207315/0/en/Abivax-Announces-Acceptance-of-22-Abstracts-Evaluating-Obefazimod-in-Inflammatory-Bowel-Disease-at-ECCO-2026-Featuring-an-Oral-Presentation-on-Preclinical-Anti-Fibrotic-Findings.html

2. https://www.stocktitan.net/news/ABVX/abivax-presents-first-evidence-of-anti-fibrotic-activity-for-8cs2c551z3pa.html

3. https://www.nasdaq.com/press-release/abivax-presents-first-evidence-anti-fibrotic-activity-obefazimod-alongside-new

4. https://www.marketscreener.com/news/positive-data-presented-for-abivax-s-obefazimod-ce7e5dd2dc89f224

5. https://medicalupdateonline.com/2025/12/abivax-to-show-22-new-abstracts-advancing-understanding-of-obefazimod-in-ibd-at-ecco-2026/